Kathryn E Falberg - Net Worth and Insider Trading
Kathryn E Falberg Net Worth
The estimated net worth of Kathryn E Falberg is at least $60 Million dollars as of 2024-05-10. Kathryn E Falberg is the Director of The Trade Desk Inc and owns about 292,609 shares of The Trade Desk Inc (TTD) stock worth over $26 Million. Kathryn E Falberg is the EVP and CFO of Jazz Pharmaceuticals PLC and owns about 124,721 shares of Jazz Pharmaceuticals PLC (JAZZ) stock worth over $14 Million. Kathryn E Falberg is also the Director of Halozyme Therapeutics Inc and owns about 280,000 shares of Halozyme Therapeutics Inc (HALO) stock worth over $12 Million. Besides these, Kathryn E Falberg also holds Aimmune Therapeutics Inc (AIMT) , Arcus Biosciences Inc (RCUS) , Nuvation Bio Inc (NUVB) , Sio Gene Therapies Inc (SIOX) , ARCA biopharma Inc (ABIO) , Tricida Inc (TCDAQ) . Details can be seen in Kathryn E Falberg's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Kathryn E Falberg has not made any transactions after 2024-03-08 and currently still holds the listed stock(s).
Transaction Summary of Kathryn E Falberg
Kathryn E Falberg Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Kathryn E Falberg owns 14 companies in total, including Aimmune Therapeutics Inc (AIMT) , Tricida Inc (TCDAQ) , and UroGen Pharma Ltd (URGN) among others .
Click here to see the complete history of Kathryn E Falberg’s form 4 insider trades.
Insider Ownership Summary of Kathryn E Falberg
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
AIMT | Aimmune Therapeutics Inc | 2020-10-10 | director |
TCDAQ | Tricida Inc | 2018-07-02 | director |
URGN | UroGen Pharma Ltd | 2019-01-01 | director |
2021-03-31 | director | ||
2024-03-08 | director | ||
2017-04-17 | director | ||
2016-09-28 | director | ||
2016-07-15 | director | ||
2015-07-08 | director | ||
2014-05-13 | director | ||
2014-02-12 | SVP and CFO | ||
2011-05-26 | director | ||
2009-02-23 | CFO and COO | ||
2022-12-05 | director |
Kathryn E Falberg Latest Holdings Summary
Kathryn E Falberg currently owns a total of 9 stocks. Among these stocks, Kathryn E Falberg owns 292,609 shares of The Trade Desk Inc (TTD) as of March 8, 2024, with a value of $26 Million and a weighting of 42.94%. Kathryn E Falberg owns 124,721 shares of Jazz Pharmaceuticals PLC (JAZZ) as of February 12, 2014, with a value of $14 Million and a weighting of 23.35%. Kathryn E Falberg also owns 280,000 shares of Halozyme Therapeutics Inc (HALO) as of August 14, 2013, with a value of $12 Million and a weighting of 20.32%. The other 6 stocks Aimmune Therapeutics Inc (AIMT) , Arcus Biosciences Inc (RCUS) , Nuvation Bio Inc (NUVB) , Sio Gene Therapies Inc (SIOX) , ARCA biopharma Inc (ABIO) , Tricida Inc (TCDAQ) have a combined weighting of 13.39% among all his current holdings.
Latest Holdings of Kathryn E Falberg
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
TTD | The Trade Desk Inc | 2024-03-08 | 292,609 | 88.67 | 25,945,640 |
JAZZ | Jazz Pharmaceuticals PLC | 2014-02-12 | 124,721 | 113.12 | 14,108,440 |
HALO | Halozyme Therapeutics Inc | 2013-08-14 | 280,000 | 43.84 | 12,275,200 |
AIMT | Aimmune Therapeutics Inc | 2018-02-26 | 124,894 | 34.49 | 4,307,594 |
RCUS | Arcus Biosciences Inc | 2021-03-31 | 182,610 | 16.15 | 2,949,152 |
NUVB | Nuvation Bio Inc | 2022-12-05 | 250,000 | 3.33 | 832,500 |
SIOX | Sio Gene Therapies Inc | 2017-04-17 | 6,742 | 0.48 | 3,223 |
ABIO | ARCA biopharma Inc | 2009-02-23 | 28 | 3.37 | 94 |
TCDAQ | Tricida Inc | 2018-07-02 | 35,211 | 0.00 | 0 |
Holding Weightings of Kathryn E Falberg
Kathryn E Falberg Form 4 Trading Tracker
According to the SEC Form 4 filings, Kathryn E Falberg has made a total of 4 transactions in The Trade Desk Inc (TTD) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in The Trade Desk Inc is the sale of 103,030 shares on March 8, 2024, which brought Kathryn E Falberg around $8 Million.
According to the SEC Form 4 filings, Kathryn E Falberg has made a total of 0 transactions in Jazz Pharmaceuticals PLC (JAZZ) over the past 5 years. The most-recent trade in Jazz Pharmaceuticals PLC is the sale of 2,000 shares on February 12, 2014, which brought Kathryn E Falberg around $314,000.
According to the SEC Form 4 filings, Kathryn E Falberg has made a total of 0 transactions in Halozyme Therapeutics Inc (HALO) over the past 5 years. The most-recent trade in Halozyme Therapeutics Inc is the acquisition of 100,000 shares on August 14, 2013, which cost Kathryn E Falberg around $682,000.
More details on Kathryn E Falberg's insider transactions can be found in the Insider Trading History of Kathryn E Falberg table.Insider Trading History of Kathryn E Falberg
- 1
Kathryn E Falberg Trading Performance
GuruFocus tracks the stock performance after each of Kathryn E Falberg's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Kathryn E Falberg is 19.34%. GuruFocus also compares Kathryn E Falberg's trading performance to market benchmark return within the same time period. The performance of stocks bought by Kathryn E Falberg within 3 months outperforms 12 times out of 17 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Kathryn E Falberg's insider trading performs compared to the benchmark.
Performance of Kathryn E Falberg
Kathryn E Falberg Ownership Network
Ownership Network List of Kathryn E Falberg
Ownership Network Relation of Kathryn E Falberg
Kathryn E Falberg Owned Company Details
What does Aimmune Therapeutics Inc do?
Who are the key executives at Aimmune Therapeutics Inc?
Kathryn E Falberg is the director of Aimmune Therapeutics Inc. Other key executives at Aimmune Therapeutics Inc include 10 percent owner Societe Des Produits Nestle S.a. , Chief Financial Officer Eric Bjerkholt , and Chief Medical Officer Adelman Daniel C Md .
Aimmune Therapeutics Inc (AIMT) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Aimmune Therapeutics Inc (AIMT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aimmune Therapeutics Inc (AIMT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Aimmune Therapeutics Inc (AIMT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aimmune Therapeutics Inc Insider Transactions
Kathryn E Falberg Mailing Address
Above is the net worth, insider trading, and ownership report for Kathryn E Falberg. You might contact Kathryn E Falberg via mailing address: C/o Axovant Sciences, Inc., 320 West 37th Street, 5th Floor, New York Ny 10018.